Ambrose Kristen's Form 4 filing
Vertex Pharmaceuticals Inc (VRTX) · filed Feb 12, 2025
- Accession no.
- 0000875320-25-000033
- Filed
- Feb 12, 2025
- Trade date
- Feb 10-11, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $632.7K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ambrose KristenCIK 0001856587 | Officer (SVP & Chief Accounting Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 10, 2025 | Common Stock | FTax withholdingDisposed | −591 | $467.98 | −$276,576.18 | 11,329 | Direct | |
| Feb 11, 2025 | Common Stock | SSaleDisposed | −1,376 | $459.83 | −$632,726.08 | 9,953 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.